News

Novarts’ biological medicine Ilaris (canakinumab) has been approved in the EU to treat adults and children as young as four years old, with cryopyrin-associated periodic syndrome (CAPS). Reportedly,

The US District Court, in In re NutriSystem securities litigation, has rejected allegations that top executives of the company had made false and misleading statements about the company’s

Nektar Therapeutics (Nektar) has completed patient enrollment ahead of schedule in its phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is company’s investigational proprietary compound

Biomerica’s new facility is the result of a two-year search of possible buildings in the Orange County area. The manufacturing layouts have taken job and process flow into

EKR Therapeutics has received notice of patent allowance from the US Patent and Trademark Office (USPTO) for its Ready-to-Use (RTU) Cardene I.V. (nicardipine hydrochloride) Premixed Injection. Once issued,

Novavax has reported that CPL Biologicals, the new joint venture between Cadila in India, has begun construction of a manufacturing facility that will be used to produce pandemic

ThromboGenics and BioInvent International (BioInvent) have completed enrollment of their phase II trial of TB-402 ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being

Astellas Pharma Europe has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for telavancin. Telavancin, a bactericidal, once-daily injectable lipoglycopeptide antibiotic, is meant for

Eisai and TSD Japan has entered into a license and joint development agreement for the development of denileukin diftitox (generic name) in Japan. Under the terms of the